sponsored
PatientsVille.com Logo

PatientsVille

Myocarditis Medical Research Studies

Up-to-date List of Myocarditis Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Myocarditis Medical Research Studies

Rank Status Study
1 Unknown  Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis
Condition: Myocarditis
Interventions: Drug: Muromonab-CD3;   Drug: Cyclosporine
Outcome Measure:
2 Recruiting CMR in Patients With Myocarditis
Condition: Suspected Acute Myocarditis
Intervention:
Outcome Measures: T1 relaxation times;   Extracellular volume (ECV)
3 Recruiting ACAM2000® Myopericarditis Registry
Conditions: Myocarditis;   Pericarditis
Intervention:
Outcome Measure: The number of confirmed, probable, suspected, and subclinical cases of myopericarditis, categorized by time since vaccination
4 Recruiting Myocardial Inflammation in Systemic Lupus Erythematosus
Condition: SLE
Intervention:
Outcome Measure: T2 edema on Cardiac MRI
5 Recruiting Oxidant-antioxidant Activity, Free Radicle Activity, Immune Response and Biomarkers in Extracorporeal Membrane Oxygenation (ECMO) Patients
Conditions: Cardiogenic Shock;   Acute Myocardial Infarction;   Myocarditis;   Cardiomyopathy
Intervention:
Outcome Measure: Mortality or multi-organ failure
6 Recruiting Cologne Register of Wearable Defibrillator (CRWD)
Conditions: Myocardial Infarction;   Ventricular Dysfunction;   Myocarditis
Intervention:
Outcome Measures: Number of arrhythmic events and arrhythmic risk factors during bridging therapy with wearable defibrillator;   Total mortality
7 Not yet recruiting A Prospective, Phase II Clinical Trial for Evaluation of G- CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy
Condition: Chronic Chagasic Myocarditis
Interventions: Drug: Treatment with G-CSF (Granulocyte colony stimulating factor);   Drug: Placebo saline
Outcome Measures: NYHA (New York Heart Association) functional class improvement;   Assessment of cardiovascular function measured by transthoracic echocardiography;   Assessment of cardiovascular function measured by cardiac magnetic resonance imaging;   Evaluation of functional capacity assessed by treadmill test and by 6-minute walk test;   Evaluation of improvement of quality of life;   Determination of tolerability
8 Not yet recruiting Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: BMS-936559;   Drug: Placebo for BMS-936559
Outcome Measures: Occurrence of a Grade 3 or greater adverse event (AE), including sign/symptom, lab toxicity, or clinical event that is definitely, probably, or possibly related to study treatment;   Occurrence of a Grade 1 or > AE of all incident adrenal insufficiency or adrenal crisis (confirmed), Myocarditis, pneumonitis, uveitis, immune-mediated hyperthyroidism or hypothyroidism, that is definitely, probably, or possibly related to study;   Frequency of HIV-1 Gag-specific CD8 T-cells by intracellular staining for interferon (IFN)-gamma at baseline and after treatment (through Day 28);   HIV-1 RNA by single copy assay (SCA) at baseline and after treatment (through Day 28);   PK parameters from non-compartmental analysis (area under curve [AUC], Cmax, V, Tmax, CL/F, t1/2);   Exploratory pharmacodynamic parameters (Emax, EC50);   HIV-1 DNA at baseline and after treatment;   Programmed cell death 1 ligand 1 (PD-L1) receptor occupancy;   Proportion of total and HIV-1 gag-specific CD8 T-cells expressing programmed cell death 1 (PD-1), PD-L1, and other exhaustion markers;   CD107a mobilization and carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution of HIV-1 gag-specific CD8 T-cells;   Polyfunctionality of HIV-1 specific CD8 and CD4 T-cells;   CD38 and human leukocyte antigen-DR (HLA-DR) expression on CD8 T-cells;   Gene expression profiles in whole blood;   Detection of antibody to study treatment in plasma;   Occurrence of a Grade 3 or greater AE, including sign/symptom, lab toxicity, or clinical event that is definitely, probably, or possibly related to study treatment;   Occurrence of a Grade 1 or > AE of all incident adrenal insufficiency or adrenal crisis (confirmed), Myocarditis, pneumonitis, uveitis, immune mediated hyperthyroidism or hypothyroidism, that is definitely, probably, or possibly related to study;   2-long terminal repeat (2LTR) circle DNA at baseline and after treatment;   Cell-associated HIV-1 RNA at baseline and after treatment;   RNA/DNA ratios in total CD4 cells at baseline and after treatment;   Expression of programmed cell death 1 ligand 2 (PD-L2) on dendritic cells and monocyte-derived macrophages
9 Recruiting CZECH-ICIT (CZECH Inflammatory Cardiomyopathy Immunosuppression Trial)
Condition: Inflammatory Cardiomyopathy
Interventions: Drug: Combination of prednisone and azathioprine;   Other: No intervention
Outcome Measures: comparison of the change in LV ejection fraction;   comparison of the change of LV end-diastolic and end-systolic diameters;   comparison of the change of New York Heart Association (NYHA) class;   comparison of total mortality;   comparison of the combined end-point;   comparison of the change in the number of infiltrating inflammatory cells in EMB
10 Not yet recruiting 18F-deoxyglucose (FDG) PET-CMD
Condition: Patients With Idiopathic Dilated Cardiomyopathy
Intervention: Drug: 18F-deoxyglucose (FDG)
Outcome Measures: Determine the percentage of patients with a diagnostic potential of the 18F-FDG PET in the detection of a significant non-cardiomyocyte hypermetabolism;   Comparison of clinical, biology, and left and ventricular remodeling at the time of diagnosis of DCM between the group of patients with significative myocardial no cardiomyocytaire uptake (FDG +) and those with no uptake (FDG -);   Evaluate the performance of 18F-FDG PET for the detection of myocardial inflammation in the initial evaluation of DCM patients compared to cardiac MRI;   Describe the different profile of FDG fixation within the group of patients FDG +;   impact of the presence or absence of a non-cardiomyocyte uptake of 18F-FDG PET at diagnosis of DCM in regard to the clinical status, ultrasound and MRI results
11 Recruiting Safety Surveillance Study of ACAM2000® Vaccinia Vaccine
Condition: Smallpox
Intervention: Biological: ACAM2000® smallpox vaccine
Outcome Measure: To provide information concerning the safety following vaccination with ACAM2000® vaccinia vaccine
12 Unknown  2D and Tissue Doppler Imaging Echocardiography Analysis of Left Ventricular Regional Wall Motion and Prognosis
Condition: Coronary Artery Disease
Intervention:
Outcome Measure: all cause mortality
13 Recruiting Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 7.5 Years Follow-up
Conditions: Coronary Heart Disease;   Heart Failure;   HIV;   AIDS;   Metabolic Syndrome
Intervention: Other: Comprehensive non invasive cardiovascular examination
Outcome Measures: Cardiovascular Diseases in HIV-infected Patients;   Cardiovascular Disorders in HIV-infected Patients HIV-HEART
14 Not yet recruiting Transient ECG Changes in Patients With Acute Biliary Disease
Conditions: Acute Cholecystitis;   Biliary Colic;   Acute Cholangitis
Intervention:
Outcome Measure:
15 Unknown  West Indies-French Guiana Dengue Study
Conditions: Fever;   Dengue
Interventions: Other: biological sample collection;   Other: quality of life questionnaire EuroQol®
Outcome Measures: Occurrence, during follow-up (for 12 weeks following symptom onset), of shock, internal bleeding, failure of one or several organs or systems (brain, heart, lung, liver, kidney, clotting system), or death.;   Onset of dengue hemorrhagic fever (WHO criteria). Changes in quality of life, measured with the EuroQol® questionnaire 3 and 12 weeks after the onset of dengue fever symptoms.
16 Recruiting Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2
Condition: Metastatic Melanoma or Renal Cell Carcinoma
Intervention: Other: Boost of radiotherapy + high dose IL-2 treatment
Outcome Measures: immunological efficacy;   Biomarkers predictive value for treatment benefit;   Toxicity;   Response Rate;   Overall Survival
17 Recruiting Escape II Myocardium
Condition: Rheumatoid Arthritis
Interventions: Drug: Triple Therapy;   Drug: TNF inhibitors
Outcome Measures: Improvement of left ventricular mass;   Improvement of Left Ventricular Ejection Fraction.;   Improvement in the degree of myocardial inflammation (as indicated by FDG uptake in PET scanning)
18 Recruiting IRon Nanoparticle Enhanced MRI in the Assessment of Myocardial infarctioN
Conditions: Myocardial Infarction;   Inflammation
Intervention: Device: Ferumoxytol enhanced MRI
Outcome Measures: R2* value;   Serum Inflammatory markers
19 Recruiting Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death
Conditions: Ischemic Cardiomyopathy;   Dilated Cardiomyopathy;   Inflammation;   Sudden Cardiac Death
Intervention:
Outcome Measures: Determine if inflammation is associated with abnormal cardiac sympathetic innervation in patients enrolled in the PROSE-ICD study.;   Determine if inflammation, measured by IL-6, is associated with abnormal cardiac sympathetic innervation, measured by MIBG imaging;   Examine the combination of CRP and MIBG to predict ICD therapies in PROSE-ICD;   Compare several MIBG imaging metrics of sympathetic innervation, in addition to the late H/M ratio, including the early H/M ratio and the MIBG washout rate, in regards to their association with biomarkers of inflammation (CRP and IL-6).
20 Unknown  Implementation of Work in Progress (WIP) Sequences in Magnetic Resonance Imaging (MRI)
Conditions: Ischemic Cardiomyopathy;   Nonischemic Cardiomyopathy
Intervention:
Outcome Measure:

These studies may lead to new treatments and are adding insight into Myocarditis etiology and treatment.

A major focus of Myocarditis research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Myocarditis